Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects
Armata Pharmaceuticals, a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial […]
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals has announced it expects to file an IND in the US in the […]
Moleculin Receives Approval in Italy to Conduct Trial for the Treatment of Acute Myeloid Leukemia
Moleculin Biotech, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting […]
Pfizer Progresses its Oral Receptor into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
Sosei Group Corporation, the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design […]
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease
Synaptogenix, an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, has announced topline data […]
Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in Combination with Tislelizumab
Phanes Therapeutics, a clinical-stage biotech company focused on innovative drug discovery and development in oncology, […]
Horizon Therapeutics Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Horizon Therapeutics has announced the first subject has been dosed in a Phase 1 randomized, […]
Generate Biomedicines Demonstrates a Novel Method of Reducing Immunogenicity through Protein Re-surfacing
Generate Biomedicines has announced that it has published data in the peer-reviewed journal Frontiers in […]
Bone Health Technologies announces positive Topline Results from Groundbreaking Pivotal Trial of Non-pharmacological Treatment for Osteopenia
Bone Health Technologies (BHT), a leading innovator of technologies for improving bone health, has announced […]
Ionis Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic form of ALS
Ionis Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted the marketing authorization application […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more